LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Search

United Therapeutics Corp

Closed

SectorHealthcare

487.65 -1.63

Overview

Share price change

24h

Current

Min

483.89

Max

496.77

Key metrics

By Trading Economics

Income

26M

364M

Sales

-9.3M

790M

P/E

Sector Avg

19.087

66.845

Profit margin

46.102

Employees

1,400

EBITDA

61M

524M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+6.6% upside

Dividends

By Dow Jones

Next Earnings

29 kwi 2026

Market Stats

By TradingEconomics

Market Cap

1.8B

23B

Previous open

489.28

Previous close

487.65

News Sentiment

By Acuity

28%

72%

80 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

United Therapeutics Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 mar 2026, 23:39 UTC

Hot Stocks

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4 mar 2026, 23:20 UTC

Earnings

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4 mar 2026, 21:43 UTC

Earnings

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4 mar 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

4 mar 2026, 23:33 UTC

Market Talk
Major News Events

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4 mar 2026, 23:24 UTC

Market Talk

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4 mar 2026, 22:30 UTC

Earnings

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4 mar 2026, 22:30 UTC

Earnings

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4 mar 2026, 22:30 UTC

Earnings

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4 mar 2026, 22:13 UTC

Earnings

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Earnings

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Earnings

Vermilion Energy 4Q EPS C$2.86 >VET

4 mar 2026, 22:04 UTC

Market Talk

RBA Slipping Behind The Curve On Rates -- Market Talk

4 mar 2026, 21:53 UTC

Earnings

Lithium Americas 4Q Rev $66.8M >LAC

4 mar 2026, 21:53 UTC

Earnings

Lithium Americas 4Q Loss/Shr 52c >LAC

4 mar 2026, 21:52 UTC

Earnings

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:50 UTC

Earnings

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4 mar 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 mar 2026, 21:48 UTC

Earnings

Webull 4Q Rev $165.2M >BULL

4 mar 2026, 21:48 UTC

Earnings

Webull 4Q EPS 1c >BULL

4 mar 2026, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 mar 2026, 21:45 UTC

Market Talk

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4 mar 2026, 21:40 UTC

Earnings

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:36 UTC

Major News Events

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4 mar 2026, 21:27 UTC

Earnings

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:17 UTC

Market Talk

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4 mar 2026, 21:16 UTC

Earnings

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4 mar 2026, 21:15 UTC

Earnings

Broadcom 1Q EPS $1.50 >AVGO

4 mar 2026, 21:15 UTC

Earnings

Broadcom 1Q Net $7.35B >AVGO

4 mar 2026, 21:15 UTC

Earnings

Broadcom 1Q Rev $19.31B >AVGO

Peer Comparison

Price change

United Therapeutics Corp Forecast

Price Target

By TipRanks

6.6% upside

12 Months Forecast

Average 531.55 USD  6.6%

High 668 USD

Low 35 USD

Based on 12 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

8

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

292.345 / 309.245Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

80 / 351 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat